EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimilars
November 05, 2015 08:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business Update
October 29, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Oct. 29, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros
September 09, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...
EPIRUS Biopharmaceuticals Reports Second Quarter 2015 Financial Results
August 07, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Aug. 07, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of...
EPIRUS Biopharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
August 04, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Aug. 04, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based, pure-play biosimilar company focused on the global development and commercialization of...
EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market
July 14, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
Profit-sharing collaboration focused on the commercialization of EPIRUS’ biosimilars pipeline in EU, Middle East, Turkey, Russia and CIS territories ("Territories")EPIRUS retains commercial rights to...
EPIRUS Biopharmaceuticals Presents New BOW015 (Infliximab Biosimilar) Data at the European League Against Rheumatism Annual Congress (EULAR 2015)
June 10, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, June 10, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of...
EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015
May 14, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, May 14, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS) and mAbxience, a biopharmaceutical company specialized in research, development and manufacturing of biosimilars,...
EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, May 12, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar...
EPIRUS Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
May 07, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar...